Cortechs.ai | Determining brain age using machine learning

Determining brain age using machine learning

Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects

Cortechs.ai’s  abstract titled “Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects” was accepted by the Radiological Society of North America.

Lead author and Cortechs.ai Principal Scientist, Weidong Luo, will present his findings at the AI Community Learning Center, Station #1 on December 5, from 12:15 – 12:45 pm.

In addition to two other presentations throughout the conference, you can find the CorTechs team at booth numbers 4055 in South Hall, Level 3 and 10514F in the AI Showcase, Level 2.

Findings

PURPOSE
Understanding brain aging may be critical to identify potential biomarkers in neurodegenerative diseases. Here we developed a machine learning based age-prediction model for metabolic and volumetric changes of normal brain structures and evaluated this model on imaging data from patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI), as well as normal subjects.
METHOD AND MATERIALS
F18-FDG PET scans and paired T1 weighted MRI brain scans for normal subjects (59-96yo, 157m/169f), MCI (56-93yo, 263m/163f) and AD (56-91yo, 121m/80f) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) imaging studies were used. All imaging data were processed by an automated brain PET activity analysis and MRI volumetric segmentation tool, PETQuant. The volumetric measurements, as well as the mean SUVR (Standardized uptake value (SUV) ratio) to the brain stem for all brain structures, were calculated. A subset of the normal test data (n=50) was reserved for testing. A brain aging model was created using a Random Forest machine learning algorithm with the normal subjects’ data. MCI and AD data were evaluated using this normal brain aging model.
RESULTS
We found the best age prediction was achieved by combining both PET and MRI measurements. For normal subjects, this model showed a high accuracy with the mean difference of -0.23 ± 3.1 years between actual and predicted age by model. In comparison, the MCI group had a mean difference of -2.12 ± 5.13 years, while the AD group had a mean difference of -3.59 ± 5.76 years. The AD subjects younger than 75 years old had the largest disparity between the actual and predicted ages. The predicted age based on PET/MRI measurements was on average 9.35 ± 4.52 year older than the actual age, while AD patients 75 years and above only showed a mean difference of -0.3 ± 3.26 years.
CONCLUSION
Our brain aging model showed a significant predicted age difference between normal and younger (<75yo) AD subjects. This suggests that accelerated brain aging could serve as an early biomarker for Alzheimer’s disease. This might help clinicians to identify younger subjects with AD and monitor their disease progression rates.
CLINICAL RELEVANCE/APPLICATION
Early diagnosis of Alzheimer’s disease and monitoring disease progression to improve patient management.

Authors: W Luo, PhD, San Diego, CA; A M Ulug, PhD; W Thompson, PhD; R Haxton; S Magda, PhD; L J Kjonigsen, MSc; et al. (wluo@cortechs.ai)

 

 

More Resources

04/10/2026

OnQ Prostate Vendor Validation: From Research to Clinical Adoption

OnQ Prostate delivers consistent, reliable AI-powered prostate MRI insights across vendors, ensuring confident diagnosis and streamlined clinical workflows.

03/20/2026

Quantitative MRI, the McDonald Criteria, and the Future of Multiple Sclerosis Care

MRI is the foundation for diagnosing and monitoring multiple sclerosis (MS)

03/13/2026

Cortechs Cares: Community Impact and Volunteer Efforts in 2025

Cortechs Cares highlights how our team gave back in 2025 through community volunteer efforts, including an Alzheimer’s Walk and holiday toy drive.

03/11/2026

OnQ™ Prostate: Bringing Quantitative MRI to Prostate Imaging

Advancing prostate MRI with quantitative diffusion biomarkers. OnQ™ Prostate brings objective RSI-based insights to support data-driven cancer evaluation.

03/04/2026

Cortechs.ai and Siemens Healthineers Partner to Expand Global Access to NeuroQuant® Technologies

NeuroQuant® Lesion Surveillance will be integrated into the Siemens Healthineers Digital Marketplace to advance quantitative brain imaging worldwide.

02/25/2026

Cortechs.ai Announces MFDS (KFDA) Approval of Global-Leading NeuroQuant® V5 Platform in South Korea

MFDS approves NeuroQuant® V5 in South Korea, expanding AI-driven volumetric neuroimaging and clinical decision support.
Scroll to Top